Analysts See $-0.05 EPS for IntelliPharmaCeutics International Inc. (IPCI)

March 14, 2018 - By Nellie Frank

 Analysts See $ 0.05 EPS for IntelliPharmaCeutics International Inc. (IPCI)

Analysts expect IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) to report $-0.05 EPS on April, 10.They anticipate $0.02 EPS change or 28.57 % from last quarter’s $-0.07 EPS. After having $-0.08 EPS previously, IntelliPharmaCeutics International Inc.’s analysts see -37.50 % EPS growth. The stock decreased 9.27% or $0.0573 during the last trading session, reaching $0.5606. About 562,884 shares traded or 56.33% up from the average. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has risen 16.57% since March 14, 2017 and is uptrending. It has underperformed by 0.13% the S&P500.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering Intellipharmaceutics Intl (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Intellipharmaceutics Intl had 8 analyst reports since December 31, 2015 according to SRatingsIntel. The firm has “Hold” rating by Maxim Group given on Friday, February 16. On Friday, June 30 the stock rating was maintained by Maxim Group with “Buy”. The firm has “Buy” rating given on Tuesday, June 6 by Maxim Group. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) earned “Buy” rating by H.C. Wainwright on Monday, February 12. The rating was maintained by Maxim Group with “Buy” on Thursday, December 31. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) earned “Buy” rating by H.C. Wainwright on Monday, March 5. As per Friday, July 21, the company rating was maintained by Maxim Group.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $19.44 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

More notable recent IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) news were published by: which released: “Intellipharmaceutics Announces Patent Litigation by Purdue against its Rexista …” on April 10, 2017, also with their article: “Intellipharmaceutics Provides Operational Update” published on January 24, 2018, published: “Intellipharmaceutics Reports on Launch of Additional Strengths of Generic …” on November 30, 2017. More interesting news about IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) were released by: and their article: “Intellipharmaceutics Announces US$4 Million Registered Direct Offering” published on October 11, 2017 as well as‘s news article titled: “Intellipharmaceutics Announces Closing of US$4 Million Financing” with publication date: October 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.